Review



mouse anti hspa5 antibody  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology mouse anti hspa5 antibody
    A Schematic of the drug affinity responsive target stability (DARTS) approach. B Western blotting of candidate proteins in replicatively senescent human dermal fibroblasts. Replicatively senescent human visceral preadipocytes (RS HPAs) were transfected with siRNA, incubated for 4 days, then treated with homoharringtonine (HHT) or phosphate buffered saline (PBS) for 4 days ( C–E ). C Cell number by CCK-8 assay ( n = 7 per group). D Immunoblots of poly (ADP-ribose) polymerase (PARP), procaspase-3 (Procasp-3) and cleaved casp-3 (Casp-3). E Quantification of Casp-3 ( n = 3 per group). F Cell number by CCK-8 assay in <t>HSPA5-overexpressing</t> HPAs ( n = 4 per group). G IHC images and quantification of HSPA5 (brown) and Casp-3 (red) in NS and RS HPAs after 2-day HHT treatment ( n = 6 fields from 2 independent experiments). Boxed region enlarged and split into HSPA5 (brown) and Casp-3 (red) channels. H Quantification of Casp-3-positive cells in HHT-treated RS HPAs with high or low HSPA5 ( n = 6 fields from 2 experiments). I Levels of HSPA5, p53, p21, and p16 proteins in HPAs at different passages. J HHT dose-response curves in HPAs at different passages (Low, P2–P3; Mid, P6–P7; High, P12–P13) (n = 5 per group). K Surface plasmon resonance affinity assay. L Predicted HHT–HSPA5 binding; H-bonds (magenta) and pi–cation (blue). M Inhibition of ATPase activity of HSPA5 by HHT and by HA15 ( n = 3 per group). N HSPA5 levels in adipose tissues of chow diet (Ch)- and high-fat diet (HF)-fed mice administered PBS or HHT ( n = 3 in Ch; n = 5 in HF). O IHC images and quantification of HSPA5 in adipose tissue of Ch- and HF-fed mice administered PBS or HHT ( n = 3 per group). P HSPA5 in adipose tissues of aged mice administered PBS or HHT ( n = 4 per group). Data are expressed as means ± SEM and analyzed via one-way ANOVA with a post-hoc test or two-tailed Student’s t test. DAB, 3,3′-diaminobenzidine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSPA5, heat shock protein family A member 5; HSPA8, heat shock protein family A member 8; PKM2, pyruvate kinase M2; RPL7, ribosomal protein L7; siSC, scrambled siRNA; TXNRD1, thioredoxin reductase 1. Illustration created in part (A) with BioRender ( https://BioRender.com/02ykozw ).
    Mouse Anti Hspa5 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1376 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+hspa5+antibody/pmc13039285-615-9-12?v=Santa+Cruz+Biotechnology
    Average 96 stars, based on 1376 article reviews
    mouse anti hspa5 antibody - by Bioz Stars, 2026-07
    96/100 stars

    Images

    1) Product Images from "Homoharringtonine exhibits senotherapeutic activity that mitigates diet- and age-associated obesity and insulin resistance and extends lifespan in mice"

    Article Title: Homoharringtonine exhibits senotherapeutic activity that mitigates diet- and age-associated obesity and insulin resistance and extends lifespan in mice

    Journal: Nature Communications

    doi: 10.1038/s41467-026-70475-3

    A Schematic of the drug affinity responsive target stability (DARTS) approach. B Western blotting of candidate proteins in replicatively senescent human dermal fibroblasts. Replicatively senescent human visceral preadipocytes (RS HPAs) were transfected with siRNA, incubated for 4 days, then treated with homoharringtonine (HHT) or phosphate buffered saline (PBS) for 4 days ( C–E ). C Cell number by CCK-8 assay ( n = 7 per group). D Immunoblots of poly (ADP-ribose) polymerase (PARP), procaspase-3 (Procasp-3) and cleaved casp-3 (Casp-3). E Quantification of Casp-3 ( n = 3 per group). F Cell number by CCK-8 assay in HSPA5-overexpressing HPAs ( n = 4 per group). G IHC images and quantification of HSPA5 (brown) and Casp-3 (red) in NS and RS HPAs after 2-day HHT treatment ( n = 6 fields from 2 independent experiments). Boxed region enlarged and split into HSPA5 (brown) and Casp-3 (red) channels. H Quantification of Casp-3-positive cells in HHT-treated RS HPAs with high or low HSPA5 ( n = 6 fields from 2 experiments). I Levels of HSPA5, p53, p21, and p16 proteins in HPAs at different passages. J HHT dose-response curves in HPAs at different passages (Low, P2–P3; Mid, P6–P7; High, P12–P13) (n = 5 per group). K Surface plasmon resonance affinity assay. L Predicted HHT–HSPA5 binding; H-bonds (magenta) and pi–cation (blue). M Inhibition of ATPase activity of HSPA5 by HHT and by HA15 ( n = 3 per group). N HSPA5 levels in adipose tissues of chow diet (Ch)- and high-fat diet (HF)-fed mice administered PBS or HHT ( n = 3 in Ch; n = 5 in HF). O IHC images and quantification of HSPA5 in adipose tissue of Ch- and HF-fed mice administered PBS or HHT ( n = 3 per group). P HSPA5 in adipose tissues of aged mice administered PBS or HHT ( n = 4 per group). Data are expressed as means ± SEM and analyzed via one-way ANOVA with a post-hoc test or two-tailed Student’s t test. DAB, 3,3′-diaminobenzidine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSPA5, heat shock protein family A member 5; HSPA8, heat shock protein family A member 8; PKM2, pyruvate kinase M2; RPL7, ribosomal protein L7; siSC, scrambled siRNA; TXNRD1, thioredoxin reductase 1. Illustration created in part (A) with BioRender ( https://BioRender.com/02ykozw ).
    Figure Legend Snippet: A Schematic of the drug affinity responsive target stability (DARTS) approach. B Western blotting of candidate proteins in replicatively senescent human dermal fibroblasts. Replicatively senescent human visceral preadipocytes (RS HPAs) were transfected with siRNA, incubated for 4 days, then treated with homoharringtonine (HHT) or phosphate buffered saline (PBS) for 4 days ( C–E ). C Cell number by CCK-8 assay ( n = 7 per group). D Immunoblots of poly (ADP-ribose) polymerase (PARP), procaspase-3 (Procasp-3) and cleaved casp-3 (Casp-3). E Quantification of Casp-3 ( n = 3 per group). F Cell number by CCK-8 assay in HSPA5-overexpressing HPAs ( n = 4 per group). G IHC images and quantification of HSPA5 (brown) and Casp-3 (red) in NS and RS HPAs after 2-day HHT treatment ( n = 6 fields from 2 independent experiments). Boxed region enlarged and split into HSPA5 (brown) and Casp-3 (red) channels. H Quantification of Casp-3-positive cells in HHT-treated RS HPAs with high or low HSPA5 ( n = 6 fields from 2 experiments). I Levels of HSPA5, p53, p21, and p16 proteins in HPAs at different passages. J HHT dose-response curves in HPAs at different passages (Low, P2–P3; Mid, P6–P7; High, P12–P13) (n = 5 per group). K Surface plasmon resonance affinity assay. L Predicted HHT–HSPA5 binding; H-bonds (magenta) and pi–cation (blue). M Inhibition of ATPase activity of HSPA5 by HHT and by HA15 ( n = 3 per group). N HSPA5 levels in adipose tissues of chow diet (Ch)- and high-fat diet (HF)-fed mice administered PBS or HHT ( n = 3 in Ch; n = 5 in HF). O IHC images and quantification of HSPA5 in adipose tissue of Ch- and HF-fed mice administered PBS or HHT ( n = 3 per group). P HSPA5 in adipose tissues of aged mice administered PBS or HHT ( n = 4 per group). Data are expressed as means ± SEM and analyzed via one-way ANOVA with a post-hoc test or two-tailed Student’s t test. DAB, 3,3′-diaminobenzidine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSPA5, heat shock protein family A member 5; HSPA8, heat shock protein family A member 8; PKM2, pyruvate kinase M2; RPL7, ribosomal protein L7; siSC, scrambled siRNA; TXNRD1, thioredoxin reductase 1. Illustration created in part (A) with BioRender ( https://BioRender.com/02ykozw ).

    Techniques Used: Western Blot, Transfection, Incubation, Saline, CCK-8 Assay, SPR Assay, Binding Assay, Inhibition, Activity Assay, Two Tailed Test



    Similar Products

    mouse anti hspa5 antibody  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology mouse anti hspa5 antibody
    A Schematic of the drug affinity responsive target stability (DARTS) approach. B Western blotting of candidate proteins in replicatively senescent human dermal fibroblasts. Replicatively senescent human visceral preadipocytes (RS HPAs) were transfected with siRNA, incubated for 4 days, then treated with homoharringtonine (HHT) or phosphate buffered saline (PBS) for 4 days ( C–E ). C Cell number by CCK-8 assay ( n = 7 per group). D Immunoblots of poly (ADP-ribose) polymerase (PARP), procaspase-3 (Procasp-3) and cleaved casp-3 (Casp-3). E Quantification of Casp-3 ( n = 3 per group). F Cell number by CCK-8 assay in <t>HSPA5-overexpressing</t> HPAs ( n = 4 per group). G IHC images and quantification of HSPA5 (brown) and Casp-3 (red) in NS and RS HPAs after 2-day HHT treatment ( n = 6 fields from 2 independent experiments). Boxed region enlarged and split into HSPA5 (brown) and Casp-3 (red) channels. H Quantification of Casp-3-positive cells in HHT-treated RS HPAs with high or low HSPA5 ( n = 6 fields from 2 experiments). I Levels of HSPA5, p53, p21, and p16 proteins in HPAs at different passages. J HHT dose-response curves in HPAs at different passages (Low, P2–P3; Mid, P6–P7; High, P12–P13) (n = 5 per group). K Surface plasmon resonance affinity assay. L Predicted HHT–HSPA5 binding; H-bonds (magenta) and pi–cation (blue). M Inhibition of ATPase activity of HSPA5 by HHT and by HA15 ( n = 3 per group). N HSPA5 levels in adipose tissues of chow diet (Ch)- and high-fat diet (HF)-fed mice administered PBS or HHT ( n = 3 in Ch; n = 5 in HF). O IHC images and quantification of HSPA5 in adipose tissue of Ch- and HF-fed mice administered PBS or HHT ( n = 3 per group). P HSPA5 in adipose tissues of aged mice administered PBS or HHT ( n = 4 per group). Data are expressed as means ± SEM and analyzed via one-way ANOVA with a post-hoc test or two-tailed Student’s t test. DAB, 3,3′-diaminobenzidine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSPA5, heat shock protein family A member 5; HSPA8, heat shock protein family A member 8; PKM2, pyruvate kinase M2; RPL7, ribosomal protein L7; siSC, scrambled siRNA; TXNRD1, thioredoxin reductase 1. Illustration created in part (A) with BioRender ( https://BioRender.com/02ykozw ).
    Mouse Anti Hspa5 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+hspa5+antibody/pmc13039285-615-9-12?v=Santa+Cruz+Biotechnology
    Average 96 stars, based on 1 article reviews
    mouse anti hspa5 antibody - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    mouse monoclonal anti grp78  (Novus Biologicals)
    94
    Novus Biologicals mouse monoclonal anti grp78
    A Schematic of the drug affinity responsive target stability (DARTS) approach. B Western blotting of candidate proteins in replicatively senescent human dermal fibroblasts. Replicatively senescent human visceral preadipocytes (RS HPAs) were transfected with siRNA, incubated for 4 days, then treated with homoharringtonine (HHT) or phosphate buffered saline (PBS) for 4 days ( C–E ). C Cell number by CCK-8 assay ( n = 7 per group). D Immunoblots of poly (ADP-ribose) polymerase (PARP), procaspase-3 (Procasp-3) and cleaved casp-3 (Casp-3). E Quantification of Casp-3 ( n = 3 per group). F Cell number by CCK-8 assay in <t>HSPA5-overexpressing</t> HPAs ( n = 4 per group). G IHC images and quantification of HSPA5 (brown) and Casp-3 (red) in NS and RS HPAs after 2-day HHT treatment ( n = 6 fields from 2 independent experiments). Boxed region enlarged and split into HSPA5 (brown) and Casp-3 (red) channels. H Quantification of Casp-3-positive cells in HHT-treated RS HPAs with high or low HSPA5 ( n = 6 fields from 2 experiments). I Levels of HSPA5, p53, p21, and p16 proteins in HPAs at different passages. J HHT dose-response curves in HPAs at different passages (Low, P2–P3; Mid, P6–P7; High, P12–P13) (n = 5 per group). K Surface plasmon resonance affinity assay. L Predicted HHT–HSPA5 binding; H-bonds (magenta) and pi–cation (blue). M Inhibition of ATPase activity of HSPA5 by HHT and by HA15 ( n = 3 per group). N HSPA5 levels in adipose tissues of chow diet (Ch)- and high-fat diet (HF)-fed mice administered PBS or HHT ( n = 3 in Ch; n = 5 in HF). O IHC images and quantification of HSPA5 in adipose tissue of Ch- and HF-fed mice administered PBS or HHT ( n = 3 per group). P HSPA5 in adipose tissues of aged mice administered PBS or HHT ( n = 4 per group). Data are expressed as means ± SEM and analyzed via one-way ANOVA with a post-hoc test or two-tailed Student’s t test. DAB, 3,3′-diaminobenzidine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSPA5, heat shock protein family A member 5; HSPA8, heat shock protein family A member 8; PKM2, pyruvate kinase M2; RPL7, ribosomal protein L7; siSC, scrambled siRNA; TXNRD1, thioredoxin reductase 1. Illustration created in part (A) with BioRender ( https://BioRender.com/02ykozw ).
    Mouse Monoclonal Anti Grp78, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+hspa5+antibody/pm41763332-96-30-34?v=Novus+Biologicals
    Average 94 stars, based on 1 article reviews
    mouse monoclonal anti grp78 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    hspa5  (R&D Systems)
    94
    R&D Systems hspa5
    A Schematic of the drug affinity responsive target stability (DARTS) approach. B Western blotting of candidate proteins in replicatively senescent human dermal fibroblasts. Replicatively senescent human visceral preadipocytes (RS HPAs) were transfected with siRNA, incubated for 4 days, then treated with homoharringtonine (HHT) or phosphate buffered saline (PBS) for 4 days ( C–E ). C Cell number by CCK-8 assay ( n = 7 per group). D Immunoblots of poly (ADP-ribose) polymerase (PARP), procaspase-3 (Procasp-3) and cleaved casp-3 (Casp-3). E Quantification of Casp-3 ( n = 3 per group). F Cell number by CCK-8 assay in <t>HSPA5-overexpressing</t> HPAs ( n = 4 per group). G IHC images and quantification of HSPA5 (brown) and Casp-3 (red) in NS and RS HPAs after 2-day HHT treatment ( n = 6 fields from 2 independent experiments). Boxed region enlarged and split into HSPA5 (brown) and Casp-3 (red) channels. H Quantification of Casp-3-positive cells in HHT-treated RS HPAs with high or low HSPA5 ( n = 6 fields from 2 experiments). I Levels of HSPA5, p53, p21, and p16 proteins in HPAs at different passages. J HHT dose-response curves in HPAs at different passages (Low, P2–P3; Mid, P6–P7; High, P12–P13) (n = 5 per group). K Surface plasmon resonance affinity assay. L Predicted HHT–HSPA5 binding; H-bonds (magenta) and pi–cation (blue). M Inhibition of ATPase activity of HSPA5 by HHT and by HA15 ( n = 3 per group). N HSPA5 levels in adipose tissues of chow diet (Ch)- and high-fat diet (HF)-fed mice administered PBS or HHT ( n = 3 in Ch; n = 5 in HF). O IHC images and quantification of HSPA5 in adipose tissue of Ch- and HF-fed mice administered PBS or HHT ( n = 3 per group). P HSPA5 in adipose tissues of aged mice administered PBS or HHT ( n = 4 per group). Data are expressed as means ± SEM and analyzed via one-way ANOVA with a post-hoc test or two-tailed Student’s t test. DAB, 3,3′-diaminobenzidine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSPA5, heat shock protein family A member 5; HSPA8, heat shock protein family A member 8; PKM2, pyruvate kinase M2; RPL7, ribosomal protein L7; siSC, scrambled siRNA; TXNRD1, thioredoxin reductase 1. Illustration created in part (A) with BioRender ( https://BioRender.com/02ykozw ).
    Hspa5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+hspa5+antibody/pm41609899-77-21-22?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    hspa5 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    mouse monoclonal anti hspa5  (Proteintech)
    96
    Proteintech mouse monoclonal anti hspa5

    Mouse Monoclonal Anti Hspa5, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+hspa5+antibody/pmc11357866-4-0-4?v=Proteintech
    Average 96 stars, based on 1 article reviews
    mouse monoclonal anti hspa5 - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    hspa5 monoclonal mouse anti human antibodies  (Danaher Inc)
    86
    Danaher Inc hspa5 monoclonal mouse anti human antibodies
    Relative mRNA expression of CDKN1A, <t>HSPA5,</t> EMC2, SLC7A11, NFE2L2, MT1G, HSPB1 and GPX4, FANCD2, CISD1, FDFT1, SLC1A5, SAT1, TFRC, RPL8, NCOA4, and LPCAT3, GLS2, DPP4, CS, ALOX15 and ACSL4 between lung squamous cell carcinoma and normal tissue. ***P<0.001. NS, not significant.
    Hspa5 Monoclonal Mouse Anti Human Antibodies, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+hspa5+antibody/pmc10921261-124-9-19?v=Danaher+Inc
    Average 86 stars, based on 1 article reviews
    hspa5 monoclonal mouse anti human antibodies - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    mouse anti-hspa5 ma5-27686  (Thermo Fisher)
    90
    Thermo Fisher mouse anti-hspa5 ma5-27686
    Relative mRNA expression of CDKN1A, <t>HSPA5,</t> EMC2, SLC7A11, NFE2L2, MT1G, HSPB1 and GPX4, FANCD2, CISD1, FDFT1, SLC1A5, SAT1, TFRC, RPL8, NCOA4, and LPCAT3, GLS2, DPP4, CS, ALOX15 and ACSL4 between lung squamous cell carcinoma and normal tissue. ***P<0.001. NS, not significant.
    Mouse Anti Hspa5 Ma5 27686, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+hspa5+antibody/pm37807968-485-13-15?v=Thermo+Fisher
    Average 90 stars, based on 1 article reviews
    mouse anti-hspa5 ma5-27686 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    mouse anti-hspa5  (Thermo Fisher)
    90
    Thermo Fisher mouse anti-hspa5
    Relative mRNA expression of CDKN1A, <t>HSPA5,</t> EMC2, SLC7A11, NFE2L2, MT1G, HSPB1 and GPX4, FANCD2, CISD1, FDFT1, SLC1A5, SAT1, TFRC, RPL8, NCOA4, and LPCAT3, GLS2, DPP4, CS, ALOX15 and ACSL4 between lung squamous cell carcinoma and normal tissue. ***P<0.001. NS, not significant.
    Mouse Anti Hspa5, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+hspa5+antibody/pmc10630885-377-14-15?v=Thermo+Fisher
    Average 90 stars, based on 1 article reviews
    mouse anti-hspa5 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A Schematic of the drug affinity responsive target stability (DARTS) approach. B Western blotting of candidate proteins in replicatively senescent human dermal fibroblasts. Replicatively senescent human visceral preadipocytes (RS HPAs) were transfected with siRNA, incubated for 4 days, then treated with homoharringtonine (HHT) or phosphate buffered saline (PBS) for 4 days ( C–E ). C Cell number by CCK-8 assay ( n = 7 per group). D Immunoblots of poly (ADP-ribose) polymerase (PARP), procaspase-3 (Procasp-3) and cleaved casp-3 (Casp-3). E Quantification of Casp-3 ( n = 3 per group). F Cell number by CCK-8 assay in HSPA5-overexpressing HPAs ( n = 4 per group). G IHC images and quantification of HSPA5 (brown) and Casp-3 (red) in NS and RS HPAs after 2-day HHT treatment ( n = 6 fields from 2 independent experiments). Boxed region enlarged and split into HSPA5 (brown) and Casp-3 (red) channels. H Quantification of Casp-3-positive cells in HHT-treated RS HPAs with high or low HSPA5 ( n = 6 fields from 2 experiments). I Levels of HSPA5, p53, p21, and p16 proteins in HPAs at different passages. J HHT dose-response curves in HPAs at different passages (Low, P2–P3; Mid, P6–P7; High, P12–P13) (n = 5 per group). K Surface plasmon resonance affinity assay. L Predicted HHT–HSPA5 binding; H-bonds (magenta) and pi–cation (blue). M Inhibition of ATPase activity of HSPA5 by HHT and by HA15 ( n = 3 per group). N HSPA5 levels in adipose tissues of chow diet (Ch)- and high-fat diet (HF)-fed mice administered PBS or HHT ( n = 3 in Ch; n = 5 in HF). O IHC images and quantification of HSPA5 in adipose tissue of Ch- and HF-fed mice administered PBS or HHT ( n = 3 per group). P HSPA5 in adipose tissues of aged mice administered PBS or HHT ( n = 4 per group). Data are expressed as means ± SEM and analyzed via one-way ANOVA with a post-hoc test or two-tailed Student’s t test. DAB, 3,3′-diaminobenzidine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSPA5, heat shock protein family A member 5; HSPA8, heat shock protein family A member 8; PKM2, pyruvate kinase M2; RPL7, ribosomal protein L7; siSC, scrambled siRNA; TXNRD1, thioredoxin reductase 1. Illustration created in part (A) with BioRender ( https://BioRender.com/02ykozw ).

    Journal: Nature Communications

    Article Title: Homoharringtonine exhibits senotherapeutic activity that mitigates diet- and age-associated obesity and insulin resistance and extends lifespan in mice

    doi: 10.1038/s41467-026-70475-3

    Figure Lengend Snippet: A Schematic of the drug affinity responsive target stability (DARTS) approach. B Western blotting of candidate proteins in replicatively senescent human dermal fibroblasts. Replicatively senescent human visceral preadipocytes (RS HPAs) were transfected with siRNA, incubated for 4 days, then treated with homoharringtonine (HHT) or phosphate buffered saline (PBS) for 4 days ( C–E ). C Cell number by CCK-8 assay ( n = 7 per group). D Immunoblots of poly (ADP-ribose) polymerase (PARP), procaspase-3 (Procasp-3) and cleaved casp-3 (Casp-3). E Quantification of Casp-3 ( n = 3 per group). F Cell number by CCK-8 assay in HSPA5-overexpressing HPAs ( n = 4 per group). G IHC images and quantification of HSPA5 (brown) and Casp-3 (red) in NS and RS HPAs after 2-day HHT treatment ( n = 6 fields from 2 independent experiments). Boxed region enlarged and split into HSPA5 (brown) and Casp-3 (red) channels. H Quantification of Casp-3-positive cells in HHT-treated RS HPAs with high or low HSPA5 ( n = 6 fields from 2 experiments). I Levels of HSPA5, p53, p21, and p16 proteins in HPAs at different passages. J HHT dose-response curves in HPAs at different passages (Low, P2–P3; Mid, P6–P7; High, P12–P13) (n = 5 per group). K Surface plasmon resonance affinity assay. L Predicted HHT–HSPA5 binding; H-bonds (magenta) and pi–cation (blue). M Inhibition of ATPase activity of HSPA5 by HHT and by HA15 ( n = 3 per group). N HSPA5 levels in adipose tissues of chow diet (Ch)- and high-fat diet (HF)-fed mice administered PBS or HHT ( n = 3 in Ch; n = 5 in HF). O IHC images and quantification of HSPA5 in adipose tissue of Ch- and HF-fed mice administered PBS or HHT ( n = 3 per group). P HSPA5 in adipose tissues of aged mice administered PBS or HHT ( n = 4 per group). Data are expressed as means ± SEM and analyzed via one-way ANOVA with a post-hoc test or two-tailed Student’s t test. DAB, 3,3′-diaminobenzidine; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSPA5, heat shock protein family A member 5; HSPA8, heat shock protein family A member 8; PKM2, pyruvate kinase M2; RPL7, ribosomal protein L7; siSC, scrambled siRNA; TXNRD1, thioredoxin reductase 1. Illustration created in part (A) with BioRender ( https://BioRender.com/02ykozw ).

    Article Snippet: Cell samples were incubated with a mixture of a mouse anti-HSPA5 antibody (Santa Cruz Biotechnology, sc-166490; 1:100) and a rabbit anti–cleaved caspase-3 antibody (Cell Signaling Technology, #9664S; 1:100) at 4 °C overnight.

    Techniques: Western Blot, Transfection, Incubation, Saline, CCK-8 Assay, SPR Assay, Binding Assay, Inhibition, Activity Assay, Two Tailed Test

    Journal: iScience

    Article Title: Cetylpyridinium chloride triggers paraptosis to suppress pancreatic tumor growth via the ERN1-MAP3K5-p38 pathway

    doi: 10.1016/j.isci.2024.110598

    Figure Lengend Snippet:

    Article Snippet: Mouse monoclonal anti-HSPA5 , Proteintech Biotechnology , Cat# 66574-1-Ig; RRID: AB_2881934.

    Techniques: Recombinant, Lysis, Modification, Polyacrylamide Gel Electrophoresis, Protease Inhibitor, CCK-8 Assay, Sequencing, Software

    Relative mRNA expression of CDKN1A, HSPA5, EMC2, SLC7A11, NFE2L2, MT1G, HSPB1 and GPX4, FANCD2, CISD1, FDFT1, SLC1A5, SAT1, TFRC, RPL8, NCOA4, and LPCAT3, GLS2, DPP4, CS, ALOX15 and ACSL4 between lung squamous cell carcinoma and normal tissue. ***P<0.001. NS, not significant.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: Relative mRNA expression of CDKN1A, HSPA5, EMC2, SLC7A11, NFE2L2, MT1G, HSPB1 and GPX4, FANCD2, CISD1, FDFT1, SLC1A5, SAT1, TFRC, RPL8, NCOA4, and LPCAT3, GLS2, DPP4, CS, ALOX15 and ACSL4 between lung squamous cell carcinoma and normal tissue. ***P<0.001. NS, not significant.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques: Expressing

    (A) Disease-free survival, (B) progression-free survival and (C) overall survival of patients with lung squamous cell carcinoma with high and low expression of HSPA5. HSPA5, heat shock protein A5.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: (A) Disease-free survival, (B) progression-free survival and (C) overall survival of patients with lung squamous cell carcinoma with high and low expression of HSPA5. HSPA5, heat shock protein A5.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques: Expressing

    The (A) univariate and (B) multivariate Cox regression revealing the HRs and P-values and certain parameters of the HSPA5, p-TNM stage, age, gender and smoking of DFS. (C) Nomogram predicting the 1-, 3- and 5-year DFS of patients with LSCC. (D) Calibration curve for the DFS nomogram in the discovery group. The dashed diagonal line represents an ideal nomogram, whereas the red, orange and blue-gray lines represent the 1-, 3- and 5-year nomograms, respectively. The (E) univariate and (F) multivariate Cox regression revealing the HRs and P-values and certain parameters of the HSPA5, p-TNM stage, age, gender and smoking of PFS. (G) Nomogram predicting the 1-, 3- and 5-year PFS of patients with LSCC. (H) Calibration curve for the PFS nomogram in the discovery group. The dashed diagonal line represents an ideal nomogram, whereas the red, orange and blue-gray lines represent the 1-, 3- and 5-year nomograms, respectively. HR, hazard ratio; DFS, disease-free survival; HSPA5, heat shock protein A5; p-TNM, pathological Tumor-Node-Metastasis; LSCC, lung squamous cell carcinoma; PFS, progression-free survival.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: The (A) univariate and (B) multivariate Cox regression revealing the HRs and P-values and certain parameters of the HSPA5, p-TNM stage, age, gender and smoking of DFS. (C) Nomogram predicting the 1-, 3- and 5-year DFS of patients with LSCC. (D) Calibration curve for the DFS nomogram in the discovery group. The dashed diagonal line represents an ideal nomogram, whereas the red, orange and blue-gray lines represent the 1-, 3- and 5-year nomograms, respectively. The (E) univariate and (F) multivariate Cox regression revealing the HRs and P-values and certain parameters of the HSPA5, p-TNM stage, age, gender and smoking of PFS. (G) Nomogram predicting the 1-, 3- and 5-year PFS of patients with LSCC. (H) Calibration curve for the PFS nomogram in the discovery group. The dashed diagonal line represents an ideal nomogram, whereas the red, orange and blue-gray lines represent the 1-, 3- and 5-year nomograms, respectively. HR, hazard ratio; DFS, disease-free survival; HSPA5, heat shock protein A5; p-TNM, pathological Tumor-Node-Metastasis; LSCC, lung squamous cell carcinoma; PFS, progression-free survival.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques:

    (A) Distribution of TIDE scores in the HSPA5 hi and HSPA5 low groups within the prediction results. (B) Expression of immune checkpoint molecules in the HSPA5 hi and HSPA5 low groups. (C) Distribution of mRNAsi scores in the HSPA5 hi and HSPA5 low groups within the prediction results. *P<0.05, ***P<0.001. NS, not significant; TIDE, tumor immune dysfunction and exclusion; HSPA5, heat shock protein A5; HSPA5 hi , high expression of HSPA5; mRNAsi, stemness index; PD-L1, programmed cell death-ligand 1; CTLA4, cytotoxic T lymphocyte-associated antigen 4; HAVCR2, hepatitis A virus cellular receptor 2; LAG3, lymphocyte activating 3; PDCD1, programmed cell death 1; PDCD1LG2, PDCD1 ligand 2; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; SIGLEC15, sialic acid binding Ig like lectin 15.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: (A) Distribution of TIDE scores in the HSPA5 hi and HSPA5 low groups within the prediction results. (B) Expression of immune checkpoint molecules in the HSPA5 hi and HSPA5 low groups. (C) Distribution of mRNAsi scores in the HSPA5 hi and HSPA5 low groups within the prediction results. *P<0.05, ***P<0.001. NS, not significant; TIDE, tumor immune dysfunction and exclusion; HSPA5, heat shock protein A5; HSPA5 hi , high expression of HSPA5; mRNAsi, stemness index; PD-L1, programmed cell death-ligand 1; CTLA4, cytotoxic T lymphocyte-associated antigen 4; HAVCR2, hepatitis A virus cellular receptor 2; LAG3, lymphocyte activating 3; PDCD1, programmed cell death 1; PDCD1LG2, PDCD1 ligand 2; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; SIGLEC15, sialic acid binding Ig like lectin 15.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques: Expressing, Virus, Binding Assay

    (A) Volcano plots of differentially expressed genes constructed using fold-change values and adjusted P-values in the HSPA5 hi and HSPA5 low groups. Red points represent the upregulated mRNAs, whereas blue points indicate the downregulated mRNAs, with statistical significance. (B) Heatmap of differentially expressed genes in the HSPA5 hi and HSPA5 low groups. KEGG signaling pathways enriched by the (C) upregulated and (D) downregulated genes in the HSPA5 hi lung squamous cell carcinoma group. HSPA5, heat shock protein A5; HSPA5 hi , high expression of HSPA5; KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix; ABC, ATP-binding cassette.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: (A) Volcano plots of differentially expressed genes constructed using fold-change values and adjusted P-values in the HSPA5 hi and HSPA5 low groups. Red points represent the upregulated mRNAs, whereas blue points indicate the downregulated mRNAs, with statistical significance. (B) Heatmap of differentially expressed genes in the HSPA5 hi and HSPA5 low groups. KEGG signaling pathways enriched by the (C) upregulated and (D) downregulated genes in the HSPA5 hi lung squamous cell carcinoma group. HSPA5, heat shock protein A5; HSPA5 hi , high expression of HSPA5; KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix; ABC, ATP-binding cassette.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques: Construct, Expressing, Binding Assay

    Correlations between HSPA5 expression and the pathway score assessed using Spearman's correlation coefficient. The abscissa represents the distribution of HSPA5 expression, whereas the ordinate represents the distribution of the pathway score. HSPA5, heat shock protein A5; TPM, transcripts per million.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: Correlations between HSPA5 expression and the pathway score assessed using Spearman's correlation coefficient. The abscissa represents the distribution of HSPA5 expression, whereas the ordinate represents the distribution of the pathway score. HSPA5, heat shock protein A5; TPM, transcripts per million.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques: Expressing

    Difference in the IC 50 values of (A) cisplatin, (B) gemcitabine, (C) docetaxel, (D) paclitaxel and (E) vinorelbine in the HSPA5 hi and HSPA5 low groups. ***P<0.001. NS, not significant; HSPA5, heat shock protein A5; HSPA5 hi , high expression of HSPA5; IC 50 , half-maximal inhibitory concentration.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: Difference in the IC 50 values of (A) cisplatin, (B) gemcitabine, (C) docetaxel, (D) paclitaxel and (E) vinorelbine in the HSPA5 hi and HSPA5 low groups. ***P<0.001. NS, not significant; HSPA5, heat shock protein A5; HSPA5 hi , high expression of HSPA5; IC 50 , half-maximal inhibitory concentration.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques: Expressing, Concentration Assay

    (A) Representative immunohistochemistry images of HSPA5 in LSCC and normal tissues (scale bars, 50 µm). (B) Quantitative analysis of the H-score indicating the expression of HSPA5 in LSCC and normal tissues. (C) Progression-free survival and (D) overall survival of LSCC in the high and low HSPA5 expression groups. ***P<0.001. HSPA5, heat shock protein A5; HSPA5 hi , high expression of HSPA5; LSCC, lung squamous cell carcinoma.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: (A) Representative immunohistochemistry images of HSPA5 in LSCC and normal tissues (scale bars, 50 µm). (B) Quantitative analysis of the H-score indicating the expression of HSPA5 in LSCC and normal tissues. (C) Progression-free survival and (D) overall survival of LSCC in the high and low HSPA5 expression groups. ***P<0.001. HSPA5, heat shock protein A5; HSPA5 hi , high expression of HSPA5; LSCC, lung squamous cell carcinoma.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques: Immunohistochemistry, Expressing

    Univariate analysis.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: Univariate analysis.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques:

    Multivariate analysis.

    Journal: Oncology Letters

    Article Title: Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

    doi: 10.3892/ol.2024.14320

    Figure Lengend Snippet: Multivariate analysis.

    Article Snippet: Thereafter, LSCC and para-cancerous tissue sections were incubated with HSPA5 monoclonal mouse anti-human antibodies (cat. no. ab21685; dilution, 1:1,000; Abcam) at 4°C overnight.

    Techniques: